Global Blood Plasma Derivatives
Global Blood Plasma Derivatives

Blood Plasma Derivatives Comprehensive Study by Type (Albumin, Anti-Thrombin III, Intravenous Immunoglobulin (IVIG), Fresh Frozen Plasma (FFP), Others), Application (Hemophilia A, Hemophilia B, HIV, Hepatitis B, Hepatitis C, Thrombocytosis, Immunodeficiency Diseases, Bleeding Disorders, Others), End User (Hospitals & Clinics, Blood Transfusion Centers, Diagnostic Centers, Others) Players and Region - Global Market Outlook to 2026

Blood Plasma Derivatives Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026 | CAGR: 9.71%  

Feb 2021 Edition 210 Pages 196 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Blood Plasma Derivatives Market Overview:
Blood Plasma Derivatives play a vital role in maintaining proper pH balance in the body and transporting nutrients throughout the body. These derivatives are derived from blood plasma on fractionation and are widely used to treat a variety of diseases. As per sources, in 2019, ~6% of all Americans were diagnosed with ‘hemophilia A’ aging between 0-4 years. In addition, the same year, ~29% of all Americans were diagnosed with ‘hemophilia B’ aging between 19-44 years. As per an estimation, ~30,000 males in the United States have hemophilia. The rising cases of hemophilia will drive the market growth in the forecast period. According to AMA, the Global Blood Plasma Derivatives market is expected to see growth rate of 9.71%

Growth Drivers
  • Rising Awareness About Blood Donations
  • Rising Geriatric Population And Occurrence Of Life-Threatening Disorders

Market Trends
  • Government Initiative To Donate Plasma To Covid Recovered Patient’s

Roadblocks
  • High Cost Of Advanced Blood Collection Devices
  • Risk Of Communicable Diseases Through Plasma Derivatives

Opportunities
  • Advancement And Development For Preservation Of Blood Plasma Derivatives
  • Opportunities From Emerging Countries

Challenges
  • Stringent Government Regulations


Competitive Landscape:
The global blood plasma derivatives market is highly competitive and consists of a limited number of vendors who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant risk factors for manufacturer’s growth. To gain a competitive edge in the market, the providers need to develop innovative technologies and stay updated with the emerging technologies that could influence their product/service lines.
Some of the key players profiled in the report are Bain Capital, LLC (United States), Baxter International Inc. (United States), Biotest AG (Germany), Grifols S.A.(Spain), Kedrion S.p.A (Italy), Octapharma AG (Switzerland), Fusion Healthcare (India), CSL Limited (Australia) and SK Plasma Co., Ltd. (Korea). Considering Market by End User, the sub-segment i.e. Hospitals & Clinics will boost the Blood Plasma Derivatives market.

The regulations such as Plasma donors should be at least 18 years old and should weigh at least 110 pounds or 50 kilograms. Moreover, the donor must be undergo non-reactive for transmissible viruses test that includes hepatitis and HIV.

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Blood Plasma Derivatives market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Blood Plasma Derivatives market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Blood Plasma Derivatives Drugs Manufacturers, Venture Capitalists, Private Equity Firms, Government Regulatory, Research Organizations and End Users.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • Albumin
  • Anti-Thrombin III
  • Intravenous Immunoglobulin (IVIG)
  • Fresh Frozen Plasma (FFP)
  • Others
By Application
  • Hemophilia A
  • Hemophilia B
  • HIV
  • Hepatitis B
  • Hepatitis C
  • Thrombocytosis
  • Immunodeficiency Diseases
  • Bleeding Disorders
  • Others
By End User
  • Hospitals & Clinics
  • Blood Transfusion Centers
  • Diagnostic Centers
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Awareness About Blood Donations
      • 3.2.2. Rising Geriatric Population And Occurrence Of Life-Threatening Disorders
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Regulations
    • 3.4. Market Trends
      • 3.4.1. Government Initiative To Donate Plasma To Covid Recovered Patient’s
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Blood Plasma Derivatives, by Type, Application, End User and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Blood Plasma Derivatives (Value)
      • 5.2.1. Global Blood Plasma Derivatives by: Type (Value)
        • 5.2.1.1. Albumin
        • 5.2.1.2. Anti-Thrombin III
        • 5.2.1.3. Intravenous Immunoglobulin (IVIG)
        • 5.2.1.4. Fresh Frozen Plasma (FFP)
        • 5.2.1.5. Others
      • 5.2.2. Global Blood Plasma Derivatives by: Application (Value)
        • 5.2.2.1. Hemophilia A
        • 5.2.2.2. Hemophilia B
        • 5.2.2.3. HIV
        • 5.2.2.4. Hepatitis B
        • 5.2.2.5. Hepatitis C
        • 5.2.2.6. Thrombocytosis
        • 5.2.2.7. Immunodeficiency Diseases
        • 5.2.2.8. Bleeding Disorders
        • 5.2.2.9. Others
      • 5.2.3. Global Blood Plasma Derivatives by: End User (Value)
        • 5.2.3.1. Hospitals & Clinics
        • 5.2.3.2. Blood Transfusion Centers
        • 5.2.3.3. Diagnostic Centers
        • 5.2.3.4. Others
      • 5.2.4. Global Blood Plasma Derivatives Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Blood Plasma Derivatives: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bain Capital, LLC (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Baxter International Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Biotest AG (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Grifols S.A.(Spain)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Kedrion S.p.A (Italy)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Octapharma AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Fusion Healthcare (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. CSL Limited (Australia)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. SK Plasma Co., Ltd. (Korea)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Blood Plasma Derivatives Sale, by Type, Application, End User and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Blood Plasma Derivatives (Value)
      • 7.2.1. Global Blood Plasma Derivatives by: Type (Value)
        • 7.2.1.1. Albumin
        • 7.2.1.2. Anti-Thrombin III
        • 7.2.1.3. Intravenous Immunoglobulin (IVIG)
        • 7.2.1.4. Fresh Frozen Plasma (FFP)
        • 7.2.1.5. Others
      • 7.2.2. Global Blood Plasma Derivatives by: Application (Value)
        • 7.2.2.1. Hemophilia A
        • 7.2.2.2. Hemophilia B
        • 7.2.2.3. HIV
        • 7.2.2.4. Hepatitis B
        • 7.2.2.5. Hepatitis C
        • 7.2.2.6. Thrombocytosis
        • 7.2.2.7. Immunodeficiency Diseases
        • 7.2.2.8. Bleeding Disorders
        • 7.2.2.9. Others
      • 7.2.3. Global Blood Plasma Derivatives by: End User (Value)
        • 7.2.3.1. Hospitals & Clinics
        • 7.2.3.2. Blood Transfusion Centers
        • 7.2.3.3. Diagnostic Centers
        • 7.2.3.4. Others
      • 7.2.4. Global Blood Plasma Derivatives Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Blood Plasma Derivatives: by Type(USD Million)
  • Table 2. Blood Plasma Derivatives Albumin , by Region USD Million (2015-2020)
  • Table 3. Blood Plasma Derivatives Anti-Thrombin III , by Region USD Million (2015-2020)
  • Table 4. Blood Plasma Derivatives Intravenous Immunoglobulin (IVIG) , by Region USD Million (2015-2020)
  • Table 5. Blood Plasma Derivatives Fresh Frozen Plasma (FFP) , by Region USD Million (2015-2020)
  • Table 6. Blood Plasma Derivatives Others , by Region USD Million (2015-2020)
  • Table 7. Blood Plasma Derivatives: by Application(USD Million)
  • Table 8. Blood Plasma Derivatives Hemophilia A , by Region USD Million (2015-2020)
  • Table 9. Blood Plasma Derivatives Hemophilia B , by Region USD Million (2015-2020)
  • Table 10. Blood Plasma Derivatives HIV , by Region USD Million (2015-2020)
  • Table 11. Blood Plasma Derivatives Hepatitis B , by Region USD Million (2015-2020)
  • Table 12. Blood Plasma Derivatives Hepatitis C , by Region USD Million (2015-2020)
  • Table 13. Blood Plasma Derivatives Thrombocytosis , by Region USD Million (2015-2020)
  • Table 14. Blood Plasma Derivatives Immunodeficiency Diseases , by Region USD Million (2015-2020)
  • Table 15. Blood Plasma Derivatives Bleeding Disorders , by Region USD Million (2015-2020)
  • Table 16. Blood Plasma Derivatives Others , by Region USD Million (2015-2020)
  • Table 17. Blood Plasma Derivatives: by End User(USD Million)
  • Table 18. Blood Plasma Derivatives Hospitals & Clinics , by Region USD Million (2015-2020)
  • Table 19. Blood Plasma Derivatives Blood Transfusion Centers , by Region USD Million (2015-2020)
  • Table 20. Blood Plasma Derivatives Diagnostic Centers , by Region USD Million (2015-2020)
  • Table 21. Blood Plasma Derivatives Others , by Region USD Million (2015-2020)
  • Table 22. South America Blood Plasma Derivatives, by Country USD Million (2015-2020)
  • Table 23. South America Blood Plasma Derivatives, by Type USD Million (2015-2020)
  • Table 24. South America Blood Plasma Derivatives, by Application USD Million (2015-2020)
  • Table 25. South America Blood Plasma Derivatives, by End User USD Million (2015-2020)
  • Table 26. Brazil Blood Plasma Derivatives, by Type USD Million (2015-2020)
  • Table 27. Brazil Blood Plasma Derivatives, by Application USD Million (2015-2020)
  • Table 28. Brazil Blood Plasma Derivatives, by End User USD Million (2015-2020)
  • Table 29. Argentina Blood Plasma Derivatives, by Type USD Million (2015-2020)
  • Table 30. Argentina Blood Plasma Derivatives, by Application USD Million (2015-2020)
  • Table 31. Argentina Blood Plasma Derivatives, by End User USD Million (2015-2020)
  • Table 32. Rest of South America Blood Plasma Derivatives, by Type USD Million (2015-2020)
  • Table 33. Rest of South America Blood Plasma Derivatives, by Application USD Million (2015-2020)
  • Table 34. Rest of South America Blood Plasma Derivatives, by End User USD Million (2015-2020)
  • Table 35. Asia Pacific Blood Plasma Derivatives, by Country USD Million (2015-2020)
  • Table 36. Asia Pacific Blood Plasma Derivatives, by Type USD Million (2015-2020)
  • Table 37. Asia Pacific Blood Plasma Derivatives, by Application USD Million (2015-2020)
  • Table 38. Asia Pacific Blood Plasma Derivatives, by End User USD Million (2015-2020)
  • Table 39. China Blood Plasma Derivatives, by Type USD Million (2015-2020)
  • Table 40. China Blood Plasma Derivatives, by Application USD Million (2015-2020)
  • Table 41. China Blood Plasma Derivatives, by End User USD Million (2015-2020)
  • Table 42. Japan Blood Plasma Derivatives, by Type USD Million (2015-2020)
  • Table 43. Japan Blood Plasma Derivatives, by Application USD Million (2015-2020)
  • Table 44. Japan Blood Plasma Derivatives, by End User USD Million (2015-2020)
  • Table 45. India Blood Plasma Derivatives, by Type USD Million (2015-2020)
  • Table 46. India Blood Plasma Derivatives, by Application USD Million (2015-2020)
  • Table 47. India Blood Plasma Derivatives, by End User USD Million (2015-2020)
  • Table 48. South Korea Blood Plasma Derivatives, by Type USD Million (2015-2020)
  • Table 49. South Korea Blood Plasma Derivatives, by Application USD Million (2015-2020)
  • Table 50. South Korea Blood Plasma Derivatives, by End User USD Million (2015-2020)
  • Table 51. Taiwan Blood Plasma Derivatives, by Type USD Million (2015-2020)
  • Table 52. Taiwan Blood Plasma Derivatives, by Application USD Million (2015-2020)
  • Table 53. Taiwan Blood Plasma Derivatives, by End User USD Million (2015-2020)
  • Table 54. Australia Blood Plasma Derivatives, by Type USD Million (2015-2020)
  • Table 55. Australia Blood Plasma Derivatives, by Application USD Million (2015-2020)
  • Table 56. Australia Blood Plasma Derivatives, by End User USD Million (2015-2020)
  • Table 57. Rest of Asia-Pacific Blood Plasma Derivatives, by Type USD Million (2015-2020)
  • Table 58. Rest of Asia-Pacific Blood Plasma Derivatives, by Application USD Million (2015-2020)
  • Table 59. Rest of Asia-Pacific Blood Plasma Derivatives, by End User USD Million (2015-2020)
  • Table 60. Europe Blood Plasma Derivatives, by Country USD Million (2015-2020)
  • Table 61. Europe Blood Plasma Derivatives, by Type USD Million (2015-2020)
  • Table 62. Europe Blood Plasma Derivatives, by Application USD Million (2015-2020)
  • Table 63. Europe Blood Plasma Derivatives, by End User USD Million (2015-2020)
  • Table 64. Germany Blood Plasma Derivatives, by Type USD Million (2015-2020)
  • Table 65. Germany Blood Plasma Derivatives, by Application USD Million (2015-2020)
  • Table 66. Germany Blood Plasma Derivatives, by End User USD Million (2015-2020)
  • Table 67. France Blood Plasma Derivatives, by Type USD Million (2015-2020)
  • Table 68. France Blood Plasma Derivatives, by Application USD Million (2015-2020)
  • Table 69. France Blood Plasma Derivatives, by End User USD Million (2015-2020)
  • Table 70. Italy Blood Plasma Derivatives, by Type USD Million (2015-2020)
  • Table 71. Italy Blood Plasma Derivatives, by Application USD Million (2015-2020)
  • Table 72. Italy Blood Plasma Derivatives, by End User USD Million (2015-2020)
  • Table 73. United Kingdom Blood Plasma Derivatives, by Type USD Million (2015-2020)
  • Table 74. United Kingdom Blood Plasma Derivatives, by Application USD Million (2015-2020)
  • Table 75. United Kingdom Blood Plasma Derivatives, by End User USD Million (2015-2020)
  • Table 76. Netherlands Blood Plasma Derivatives, by Type USD Million (2015-2020)
  • Table 77. Netherlands Blood Plasma Derivatives, by Application USD Million (2015-2020)
  • Table 78. Netherlands Blood Plasma Derivatives, by End User USD Million (2015-2020)
  • Table 79. Rest of Europe Blood Plasma Derivatives, by Type USD Million (2015-2020)
  • Table 80. Rest of Europe Blood Plasma Derivatives, by Application USD Million (2015-2020)
  • Table 81. Rest of Europe Blood Plasma Derivatives, by End User USD Million (2015-2020)
  • Table 82. MEA Blood Plasma Derivatives, by Country USD Million (2015-2020)
  • Table 83. MEA Blood Plasma Derivatives, by Type USD Million (2015-2020)
  • Table 84. MEA Blood Plasma Derivatives, by Application USD Million (2015-2020)
  • Table 85. MEA Blood Plasma Derivatives, by End User USD Million (2015-2020)
  • Table 86. Middle East Blood Plasma Derivatives, by Type USD Million (2015-2020)
  • Table 87. Middle East Blood Plasma Derivatives, by Application USD Million (2015-2020)
  • Table 88. Middle East Blood Plasma Derivatives, by End User USD Million (2015-2020)
  • Table 89. Africa Blood Plasma Derivatives, by Type USD Million (2015-2020)
  • Table 90. Africa Blood Plasma Derivatives, by Application USD Million (2015-2020)
  • Table 91. Africa Blood Plasma Derivatives, by End User USD Million (2015-2020)
  • Table 92. North America Blood Plasma Derivatives, by Country USD Million (2015-2020)
  • Table 93. North America Blood Plasma Derivatives, by Type USD Million (2015-2020)
  • Table 94. North America Blood Plasma Derivatives, by Application USD Million (2015-2020)
  • Table 95. North America Blood Plasma Derivatives, by End User USD Million (2015-2020)
  • Table 96. United States Blood Plasma Derivatives, by Type USD Million (2015-2020)
  • Table 97. United States Blood Plasma Derivatives, by Application USD Million (2015-2020)
  • Table 98. United States Blood Plasma Derivatives, by End User USD Million (2015-2020)
  • Table 99. Canada Blood Plasma Derivatives, by Type USD Million (2015-2020)
  • Table 100. Canada Blood Plasma Derivatives, by Application USD Million (2015-2020)
  • Table 101. Canada Blood Plasma Derivatives, by End User USD Million (2015-2020)
  • Table 102. Mexico Blood Plasma Derivatives, by Type USD Million (2015-2020)
  • Table 103. Mexico Blood Plasma Derivatives, by Application USD Million (2015-2020)
  • Table 104. Mexico Blood Plasma Derivatives, by End User USD Million (2015-2020)
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Blood Plasma Derivatives: by Type(USD Million)
  • Table 115. Blood Plasma Derivatives Albumin , by Region USD Million (2021-2026)
  • Table 116. Blood Plasma Derivatives Anti-Thrombin III , by Region USD Million (2021-2026)
  • Table 117. Blood Plasma Derivatives Intravenous Immunoglobulin (IVIG) , by Region USD Million (2021-2026)
  • Table 118. Blood Plasma Derivatives Fresh Frozen Plasma (FFP) , by Region USD Million (2021-2026)
  • Table 119. Blood Plasma Derivatives Others , by Region USD Million (2021-2026)
  • Table 120. Blood Plasma Derivatives: by Application(USD Million)
  • Table 121. Blood Plasma Derivatives Hemophilia A , by Region USD Million (2021-2026)
  • Table 122. Blood Plasma Derivatives Hemophilia B , by Region USD Million (2021-2026)
  • Table 123. Blood Plasma Derivatives HIV , by Region USD Million (2021-2026)
  • Table 124. Blood Plasma Derivatives Hepatitis B , by Region USD Million (2021-2026)
  • Table 125. Blood Plasma Derivatives Hepatitis C , by Region USD Million (2021-2026)
  • Table 126. Blood Plasma Derivatives Thrombocytosis , by Region USD Million (2021-2026)
  • Table 127. Blood Plasma Derivatives Immunodeficiency Diseases , by Region USD Million (2021-2026)
  • Table 128. Blood Plasma Derivatives Bleeding Disorders , by Region USD Million (2021-2026)
  • Table 129. Blood Plasma Derivatives Others , by Region USD Million (2021-2026)
  • Table 130. Blood Plasma Derivatives: by End User(USD Million)
  • Table 131. Blood Plasma Derivatives Hospitals & Clinics , by Region USD Million (2021-2026)
  • Table 132. Blood Plasma Derivatives Blood Transfusion Centers , by Region USD Million (2021-2026)
  • Table 133. Blood Plasma Derivatives Diagnostic Centers , by Region USD Million (2021-2026)
  • Table 134. Blood Plasma Derivatives Others , by Region USD Million (2021-2026)
  • Table 135. South America Blood Plasma Derivatives, by Country USD Million (2021-2026)
  • Table 136. South America Blood Plasma Derivatives, by Type USD Million (2021-2026)
  • Table 137. South America Blood Plasma Derivatives, by Application USD Million (2021-2026)
  • Table 138. South America Blood Plasma Derivatives, by End User USD Million (2021-2026)
  • Table 139. Brazil Blood Plasma Derivatives, by Type USD Million (2021-2026)
  • Table 140. Brazil Blood Plasma Derivatives, by Application USD Million (2021-2026)
  • Table 141. Brazil Blood Plasma Derivatives, by End User USD Million (2021-2026)
  • Table 142. Argentina Blood Plasma Derivatives, by Type USD Million (2021-2026)
  • Table 143. Argentina Blood Plasma Derivatives, by Application USD Million (2021-2026)
  • Table 144. Argentina Blood Plasma Derivatives, by End User USD Million (2021-2026)
  • Table 145. Rest of South America Blood Plasma Derivatives, by Type USD Million (2021-2026)
  • Table 146. Rest of South America Blood Plasma Derivatives, by Application USD Million (2021-2026)
  • Table 147. Rest of South America Blood Plasma Derivatives, by End User USD Million (2021-2026)
  • Table 148. Asia Pacific Blood Plasma Derivatives, by Country USD Million (2021-2026)
  • Table 149. Asia Pacific Blood Plasma Derivatives, by Type USD Million (2021-2026)
  • Table 150. Asia Pacific Blood Plasma Derivatives, by Application USD Million (2021-2026)
  • Table 151. Asia Pacific Blood Plasma Derivatives, by End User USD Million (2021-2026)
  • Table 152. China Blood Plasma Derivatives, by Type USD Million (2021-2026)
  • Table 153. China Blood Plasma Derivatives, by Application USD Million (2021-2026)
  • Table 154. China Blood Plasma Derivatives, by End User USD Million (2021-2026)
  • Table 155. Japan Blood Plasma Derivatives, by Type USD Million (2021-2026)
  • Table 156. Japan Blood Plasma Derivatives, by Application USD Million (2021-2026)
  • Table 157. Japan Blood Plasma Derivatives, by End User USD Million (2021-2026)
  • Table 158. India Blood Plasma Derivatives, by Type USD Million (2021-2026)
  • Table 159. India Blood Plasma Derivatives, by Application USD Million (2021-2026)
  • Table 160. India Blood Plasma Derivatives, by End User USD Million (2021-2026)
  • Table 161. South Korea Blood Plasma Derivatives, by Type USD Million (2021-2026)
  • Table 162. South Korea Blood Plasma Derivatives, by Application USD Million (2021-2026)
  • Table 163. South Korea Blood Plasma Derivatives, by End User USD Million (2021-2026)
  • Table 164. Taiwan Blood Plasma Derivatives, by Type USD Million (2021-2026)
  • Table 165. Taiwan Blood Plasma Derivatives, by Application USD Million (2021-2026)
  • Table 166. Taiwan Blood Plasma Derivatives, by End User USD Million (2021-2026)
  • Table 167. Australia Blood Plasma Derivatives, by Type USD Million (2021-2026)
  • Table 168. Australia Blood Plasma Derivatives, by Application USD Million (2021-2026)
  • Table 169. Australia Blood Plasma Derivatives, by End User USD Million (2021-2026)
  • Table 170. Rest of Asia-Pacific Blood Plasma Derivatives, by Type USD Million (2021-2026)
  • Table 171. Rest of Asia-Pacific Blood Plasma Derivatives, by Application USD Million (2021-2026)
  • Table 172. Rest of Asia-Pacific Blood Plasma Derivatives, by End User USD Million (2021-2026)
  • Table 173. Europe Blood Plasma Derivatives, by Country USD Million (2021-2026)
  • Table 174. Europe Blood Plasma Derivatives, by Type USD Million (2021-2026)
  • Table 175. Europe Blood Plasma Derivatives, by Application USD Million (2021-2026)
  • Table 176. Europe Blood Plasma Derivatives, by End User USD Million (2021-2026)
  • Table 177. Germany Blood Plasma Derivatives, by Type USD Million (2021-2026)
  • Table 178. Germany Blood Plasma Derivatives, by Application USD Million (2021-2026)
  • Table 179. Germany Blood Plasma Derivatives, by End User USD Million (2021-2026)
  • Table 180. France Blood Plasma Derivatives, by Type USD Million (2021-2026)
  • Table 181. France Blood Plasma Derivatives, by Application USD Million (2021-2026)
  • Table 182. France Blood Plasma Derivatives, by End User USD Million (2021-2026)
  • Table 183. Italy Blood Plasma Derivatives, by Type USD Million (2021-2026)
  • Table 184. Italy Blood Plasma Derivatives, by Application USD Million (2021-2026)
  • Table 185. Italy Blood Plasma Derivatives, by End User USD Million (2021-2026)
  • Table 186. United Kingdom Blood Plasma Derivatives, by Type USD Million (2021-2026)
  • Table 187. United Kingdom Blood Plasma Derivatives, by Application USD Million (2021-2026)
  • Table 188. United Kingdom Blood Plasma Derivatives, by End User USD Million (2021-2026)
  • Table 189. Netherlands Blood Plasma Derivatives, by Type USD Million (2021-2026)
  • Table 190. Netherlands Blood Plasma Derivatives, by Application USD Million (2021-2026)
  • Table 191. Netherlands Blood Plasma Derivatives, by End User USD Million (2021-2026)
  • Table 192. Rest of Europe Blood Plasma Derivatives, by Type USD Million (2021-2026)
  • Table 193. Rest of Europe Blood Plasma Derivatives, by Application USD Million (2021-2026)
  • Table 194. Rest of Europe Blood Plasma Derivatives, by End User USD Million (2021-2026)
  • Table 195. MEA Blood Plasma Derivatives, by Country USD Million (2021-2026)
  • Table 196. MEA Blood Plasma Derivatives, by Type USD Million (2021-2026)
  • Table 197. MEA Blood Plasma Derivatives, by Application USD Million (2021-2026)
  • Table 198. MEA Blood Plasma Derivatives, by End User USD Million (2021-2026)
  • Table 199. Middle East Blood Plasma Derivatives, by Type USD Million (2021-2026)
  • Table 200. Middle East Blood Plasma Derivatives, by Application USD Million (2021-2026)
  • Table 201. Middle East Blood Plasma Derivatives, by End User USD Million (2021-2026)
  • Table 202. Africa Blood Plasma Derivatives, by Type USD Million (2021-2026)
  • Table 203. Africa Blood Plasma Derivatives, by Application USD Million (2021-2026)
  • Table 204. Africa Blood Plasma Derivatives, by End User USD Million (2021-2026)
  • Table 205. North America Blood Plasma Derivatives, by Country USD Million (2021-2026)
  • Table 206. North America Blood Plasma Derivatives, by Type USD Million (2021-2026)
  • Table 207. North America Blood Plasma Derivatives, by Application USD Million (2021-2026)
  • Table 208. North America Blood Plasma Derivatives, by End User USD Million (2021-2026)
  • Table 209. United States Blood Plasma Derivatives, by Type USD Million (2021-2026)
  • Table 210. United States Blood Plasma Derivatives, by Application USD Million (2021-2026)
  • Table 211. United States Blood Plasma Derivatives, by End User USD Million (2021-2026)
  • Table 212. Canada Blood Plasma Derivatives, by Type USD Million (2021-2026)
  • Table 213. Canada Blood Plasma Derivatives, by Application USD Million (2021-2026)
  • Table 214. Canada Blood Plasma Derivatives, by End User USD Million (2021-2026)
  • Table 215. Mexico Blood Plasma Derivatives, by Type USD Million (2021-2026)
  • Table 216. Mexico Blood Plasma Derivatives, by Application USD Million (2021-2026)
  • Table 217. Mexico Blood Plasma Derivatives, by End User USD Million (2021-2026)
  • Table 218. Research Programs/Design for This Report
  • Table 219. Key Data Information from Secondary Sources
  • Table 220. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Blood Plasma Derivatives: by Type USD Million (2015-2020)
  • Figure 5. Global Blood Plasma Derivatives: by Application USD Million (2015-2020)
  • Figure 6. Global Blood Plasma Derivatives: by End User USD Million (2015-2020)
  • Figure 7. South America Blood Plasma Derivatives Share (%), by Country
  • Figure 8. Asia Pacific Blood Plasma Derivatives Share (%), by Country
  • Figure 9. Europe Blood Plasma Derivatives Share (%), by Country
  • Figure 10. MEA Blood Plasma Derivatives Share (%), by Country
  • Figure 11. North America Blood Plasma Derivatives Share (%), by Country
  • Figure 12. Global Blood Plasma Derivatives share by Players 2020 (%)
  • Figure 13. Global Blood Plasma Derivatives share by Players (Top 3) 2020(%)
  • Figure 14. Global Blood Plasma Derivatives share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Bain Capital, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 17. Bain Capital, LLC (United States) Revenue: by Geography 2020
  • Figure 18. Baxter International Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Baxter International Inc. (United States) Revenue: by Geography 2020
  • Figure 20. Biotest AG (Germany) Revenue, Net Income and Gross profit
  • Figure 21. Biotest AG (Germany) Revenue: by Geography 2020
  • Figure 22. Grifols S.A.(Spain) Revenue, Net Income and Gross profit
  • Figure 23. Grifols S.A.(Spain) Revenue: by Geography 2020
  • Figure 24. Kedrion S.p.A (Italy) Revenue, Net Income and Gross profit
  • Figure 25. Kedrion S.p.A (Italy) Revenue: by Geography 2020
  • Figure 26. Octapharma AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 27. Octapharma AG (Switzerland) Revenue: by Geography 2020
  • Figure 28. Fusion Healthcare (India) Revenue, Net Income and Gross profit
  • Figure 29. Fusion Healthcare (India) Revenue: by Geography 2020
  • Figure 30. CSL Limited (Australia) Revenue, Net Income and Gross profit
  • Figure 31. CSL Limited (Australia) Revenue: by Geography 2020
  • Figure 32. SK Plasma Co., Ltd. (Korea) Revenue, Net Income and Gross profit
  • Figure 33. SK Plasma Co., Ltd. (Korea) Revenue: by Geography 2020
  • Figure 34. Global Blood Plasma Derivatives: by Type USD Million (2021-2026)
  • Figure 35. Global Blood Plasma Derivatives: by Application USD Million (2021-2026)
  • Figure 36. Global Blood Plasma Derivatives: by End User USD Million (2021-2026)
  • Figure 37. South America Blood Plasma Derivatives Share (%), by Country
  • Figure 38. Asia Pacific Blood Plasma Derivatives Share (%), by Country
  • Figure 39. Europe Blood Plasma Derivatives Share (%), by Country
  • Figure 40. MEA Blood Plasma Derivatives Share (%), by Country
  • Figure 41. North America Blood Plasma Derivatives Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Bain Capital, LLC (United States)
  • Baxter International Inc. (United States)
  • Biotest AG (Germany)
  • Grifols S.A.(Spain)
  • Kedrion S.p.A (Italy)
  • Octapharma AG (Switzerland)
  • Fusion Healthcare (India)
  • CSL Limited (Australia)
  • SK Plasma Co., Ltd. (Korea)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation